Report in the journal _Circulation_ that aspirin is cost effective at a younger age and lower 10-year baseline CV risk in men than it is in women.(University Medical Center Utrecht, The Netherlands) and team developed a Markov model using event rates taken from Dutch population data and relative effectiveness of aspirin taken from a gender-specific meta-analysis.Used this decision model to determine the costs and effects of aspirinpared with no treatment in initially healthy men or women aged 45, 55, 65, or 75 years, without a history of CV disease.Cost-effective for men with a 10-year CV risk >10% and for women >15%," they write.General, this occurs much later in life for women than men.Threshold of €20,000 (US$31,000) per quality-adjusted life year (QALY), aspirin treatment was cost effective for men aged 75 years irrespective of CV risk, and for those aged 55 and 65 years with two or more classic CV risk factors.Treatment with aspirin was cost effective in women aged 75 years only if they had at least a two-fold increased CV risk, and in those aged 65 years with a five-fold increased CV risk.55 years appeared to have no QALY gain with aspirin treatment: the number of ischemic events prevented was too small to outweigh the increase in hemorrhagic stroke and gastrointestinal bleeding.Prevention aspirin seem limited in women, and a gender-differentiated preventive strategy seems warranted," Greving _et al_ conclude.Related editorial, Lori Mosca (Columbia University Medical Center, New York, USA)mented that the data "support a more conservative approach to aspirin for primary prevention in younger versus older women, consistent with current guidelines.Read more Amiodarone hydrochloride(amiodarone hydrochloride) tablet [barr laboratories, inc.]
Get more Changes in relative potency among positive gabaa receptor modulators upon discontinuation of chronic benzodiazepine treatment in rhesus monkeys
